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Strengths and limitations of this study
 ► A wide- ranging literature search examined the im-
pact of 12 randomised clinical trial reports affected 
by misconduct.
 ► A detailed examination of the extent and effect of 
these trial reports on guidelines, systematic and oth-
er reviews, and clinical trials was undertaken.
 ► We only examined the impact of 12/27 retracted trial 
reports, and assessing the impact on citing publi-
cations would have been strengthened if we had 
contacted the authors of the 68 citing publications.
 ► We only examined the effect on published research 
we were able to identify, and probably have not 
found all publications, especially guidelines. We did 
not examine impact on other forms of influence, 
for example, grant applications, drug company 
documents.
AbStrACt
Objective Analyses of the impact of a body of clinical trial 
reports subject to research misconduct have been few. Our 
objective was to examine the impact on clinically relevant 
research of a group of researchers’ trial reports (‘affected 
trial reports’) affected by research misconduct, and 
whether identification of misconduct invoked a reappraisal.
Design In 2016, we used five databases and search 
engines to identify ‘citing publications’, that is, guidelines, 
systematic and other reviews, and clinical trials citing 
any of 12 affected trial reports, published 1998–2011, 
eventually retracted for research misconduct. The affected 
trial reports were assessed more likely to have had impact 
because they had hip fracture outcomes and were in 
journals with impact factor >4. Two authors assessed 
whether findings of the citing publications would change 
if the affected trial reports were removed. In 2018, we 
searched for evidence that the citing publications had 
undertaken a reassessment as a result of the potential 
influence of the affected trial reports.
results By 2016 the affected trial reports were cited in 
1158 publications, including 68 systematic reviews, meta- 
analyses, narrative reviews, guidelines and clinical trials. 
We judged that 13 guidelines, systematic or other reviews 
would likely change their findings if the affected trial 
reports were removed, and in another eight it was unclear 
if findings would change. By 2018, only one of the 68 
citing publications, a systematic review, appeared to have 
undertaken a reassessment, which led to a correction.
Conclusions We found evidence that this group of 
affected trial reports distorted the evidence base. 
Correction of these distortions is slow, uncoordinated 
and inconsistent. Unless there is a rapid, systematic, 
coordinated approach by bibliographic databases, authors, 
journals and publishers to mitigate the impact of known 
cases of research misconduct, patients, other researchers 
and their funders may continue to be adversely affected.
bACkgrOunD
We raised concerns about 33 randomised 
controlled trial (RCT) reports, ‘affected trial 
reports’, from one research group in Japan 
(see online supplementary appendix for list of 
33 RCTs).1 2 Our systematic review published 
in November 2016 examined these affected 
trial reports published in the field of osteopo-
rosis over 15 years. The affected trial reports 
ostensibly involved large numbers of older 
patients with significant comorbidities, such 
as stroke, Alzheimer’s disease and Parkinson’s 
disease.1 In September 2016, the editor of the 
journal that published our systematic review 
conveyed the results of its investigations to all 
the journals with affected trial reports. By May 
2019, 27/33 of these affected trial reports had 
been retracted for reasons including fabrica-
tion, plagiarism, authorship misconduct and 
unresolved concerns about data integrity.
Retraction of a research paper may have 
important implications for clinical practice 
and present and future research initiatives. 
Patients and research participants may be put 
at risk if decisions are based on findings that 
are later retracted because they were incor-
rect or unreliable.3 4 It is therefore important 
to determine the extent of a retracted paper’s 
influence, for example, through citations in 
other influential publications, such as system-
atic reviews and guidelines, and its use in 
copyright.
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initiating new research. There is evidence that authors of 
publications that cite retracted work remain unaware of 
the retraction,5 and this has potentially important conse-
quences for their work, that of subsequent researchers, 
and for clinical practitioners and patients.
Analyses of the impact of a body of clinical trial reports 
subject to research misconduct have been few. Our objec-
tive was to examine the impact and influence of a selec-
tion of the published affected trial reports most likely to 
affect clinical guidance and practice and further research. 
We focused on affected trial reports with hip fracture 
outcome data in influential journals.
MethODS
Search criteria
We studied the impact of a subgroup of the 33 affected 
trial reports whose integrity was analysed in our systematic 
review.1 This subgroup of trial reports was used because 
these trials had hip fracture as an outcome, arguably 
the most important consequence of osteoporosis, and 
affected trial reports on this outcome are likely to have 
the greatest impact. We included all affected trial reports 
with hip fracture outcomes that had also been published 
in higher impact journals (ISI Web of Knowledge impact 
factor >4).
evidence identification
In August 2016, we used Scopus and Web of Science to 
find citations of each affected trial report and the type 
of publication that cited each report (‘citing publica-
tions’—guidelines, systematic and other reviews, and 
clinical trials). We also searched Google Scholar, PubMed 
and personal databases to identify systematic reviews, 
meta- analyses, narrative reviews and guidelines relating to 
hip fracture prevention, which potentially would include 
these affected trial reports. Finally, we sought other 
types of publications that cited the affected trial reports, 
through an iterative process, for example, using the 
following search command in Ovid MEDLINE: ( sato. tw) 
and ((letter or  comment$). pt). We excluded self- citing 
publications by authors of affected trial reports from our 
evaluations.
Assessment of impact
Where possible, meta- analyses which included data 
from affected trial reports were reanalysed to investigate 
whether the quantitative findings, such as summary risk 
ratios in forest plots, would change without the inclusion 
of those data. In the case of reviews in which data from 
affected trial reports were not included in quantitative 
synthesis, we used our judgement. One investigator (FS) 
initially assessed all citing publications for the influence 
of affected trial reports, which were then discussed in 
depth with a second investigator (AA). Agreement was 
reached between AA and FS on all affected publications, 
apart from two where AG and MB provided input leading 
to consensus. We categorised affected publications 
according to the likelihood of a change in findings if the 
affected trial reports were excluded:
1. Findings likely to change.
2. Uncertain if findings would change.
3. Findings unlikely to change.
In November 2018, we searched again Web of Science, 
Scopus or guideline websites to see if the affected system-
atic reviews, meta- analyses, narrative reviews and guide-
lines, identified in August 2016, had published any 
notice, update, correction or retraction on publishers’ 
websites resulting from recognition that the publication 
was potentially influenced by the affected trial reports. 
We searched Web of Science, or Scopus if not included in 
Web of Science, to identify the number of times the citing 
publications we had judged likely or possibly to have been 
influenced by affected trial reports had themselves ever 
been cited, and the date of the most recent citation.
In July 2019, we searched Web of Science for any 
publication that cited the affected trial reports after they 
had been retracted, to examine whether these publica-
tions mentioned that the affected trial reports had been 
retracted.
Patient and public involvement
We did not involve patients or the public in our work.
reSultS
Twelve trial reports from the original 33 were identified 
by us for evaluation. These 12 affected trial reports all had 
hip fracture outcomes and were published between 1997 
and 2011 in journals with impact factors>4, with 3182 
reported participants (table 1).6–17 They were published 
in journals with a median impact factor of 5.8 (range from 
4.57 9 10 to 3014). All 12 affected trial reports were retracted 
between June 2016 and April 2019, but by July 2019 only 7 
(58%) were marked as retractions on both Ovid Medline 
and PubMed,9 10 12–15 17 and two further affected trial 
reports were marked as retracted on PubMed but not on 
Medline.11 16
We examined 40 publications in July 2019 that cited any 
of the 12 affected trial reports after they were retracted. 
Thirty- four publications (85%) expressed no concern 
about the affected trial reports, and six (15%) cited the 
affected trial reports but discounted their findings as a 
result of misconduct.
Citations of affected trial reports
By August 2016, the 12 affected trial reports were cited a 
total of 1158 times in publications of any kind, identified 
by our literature searches. The median number of cita-
tions for affected trial reports was 84 (range 14 to 323).
Sixty- eight systematic reviews, meta- analyses, narrative 
reviews, guidelines and clinical trials cited at least one 
of the 12 affected trial reports. Each affected trial report 
was cited by a median of 11 of the 68 publications (range 
one to 25). Five citing publications, including Agency for 
Healthcare Research and Quality (AHRQ) comparative 
copyright.
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Table 1 Affected trial reports in journals with impact factor >4 and hip fracture outcome data
Citation Intervention
Journal 
impact 
factor
Hip fracture data Times cited 
by any of 
the affected 
publications*
Google Scholar 
total citations 
August 2016Control Intervention
(Retracted April 2019) Sato Y, et 
al. Amelioration of hemiplegia- 
associated osteopenia more 
than 4 years after stroke by 
1 alpha- hydroxyvitamin D3 
and calcium supplementation. 
Stroke 1997;28:736–9.6
Alphacalcidiol 
v placebo
6 4/39 0/45 8 80
(Retracted October 2018) 
Sato Y, et al. Menatetrenone 
ameliorates osteopenia in 
disuse- affected limbs of vitamin 
D- and K- deficient stroke 
patients. Bone 1998;23:291–6.7
Vitamin K v nil 4.5 1/54 0/54 6 94
(Retracted August 2017) Sato Y, 
et al. Amelioration of osteopenia 
and hypovitaminosis D by 
1alpha- hydroxyvitamin D3 in 
elderly patients with Parkinson’s 
disease. J Neurol Neurosurg 
Psychiatry 1999;66:64–68.8
Alphacalcidiol 
v placebo
5.6 6/43 1/43 11 105
(Retracted September 2017) 
#Sato Y, et al. Amelioration of 
osteoporosis by menatetrenone 
in elderly female Parkinson's 
disease patients with vitamin D 
deficiency. Bone 2002;31:114–
8.9
Vitamin K v nil 4.5 8/60 1/60 4 93
(Retracted October 2017) 
#Sato Y, et al. Menatetrenone 
and vitamin D2 with calcium 
supplements prevent 
nonvertebral fracture in elderly 
women with Alzheimer's 
disease. Bone 2005;36:61–8.10
Vitamin K/ 
vitamin D/ 
calcium v nil
4.5 15/100 2/100 12 55
(Retracted July 2016) Sato 
Y, et al. Risedronate therapy 
for prevention of hip fracture 
after stroke in elderly women. 
Neurology 2005;64:811–6.11
Risedronate v 
placebo
8.3 7/187 1/187 13 88
(Retracted June 2016) #Sato 
Y, et al. Risedronate sodium 
therapy for prevention of hip 
fracture in men 65 years or 
older after stroke. Arch Intern 
Med 2005;165:1743–8.12
Risedronate v 
placebo
13.3 10/140 2/140 19 139
(Retracted June 2016) #Sato 
Y, et al. The prevention of hip 
fracture with risedronate and 
ergocalciferol plus calcium 
supplementation in elderly 
women with Alzheimer 
disease: a randomized 
controlled trial. Arch Intern Med 
2005;165:1737–42.13
Risedronate v 
placebo
13.3 19/250 5/250 12 61
Continued
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Citation Intervention
Journal 
impact 
factor
Hip fracture data Times cited 
by any of 
the affected 
publications*
Google Scholar 
total citations 
August 2016Control Intervention
(Retracted June 2016) #Sato 
Y, et al. Effect of folate and 
mecobalamin on hip fractures 
in patients with stroke: a 
randomized controlled trial. 
JAMA 2005;293:1082–8.14
B12/folate v 
placebo
30 27/314 6/314 25 323
(Retracted June 2016) #Sato Y, 
et al. Alendronate and vitamin 
D2 for prevention of hip fracture 
in Parkinson's disease: a 
randomized controlled trial. Mov 
Disord 2006;21:924–9.15
Alendronate v 
placebo
5.4 14/144 4/144 11 44
(Retracted July 2016) Sato 
Y, et al. Risedronate and 
ergocalciferol prevent hip 
fracture in elderly men with 
Parkinson disease. Neurology 
2007;68:911–5.16
Risedronate v 
placebo
8.3 9/121 3/121 9 62
(Retracted April 2017) 
#Sato Y, et al. Once- weekly 
risedronate for prevention 
of hip fracture in women 
with Parkinson's disease: a 
randomised controlled trial. J 
Neurol Neurosurg Psychiatry 
2011;82:1390–3.17
Risedronate v 
placebo
5.6 15/136 33/136 1 14
#Marked as retracted on both PubMed and Ovid Medline by July 2019. Retraction dates relate to online posting.
*Publications of interest: 68 systematic reviews, meta- analyses, narrative reviews, guidelines and clinical trials citing at least one of the 12 
affected trial reports.
Table 1 Continued
Table 2 Number of reports citing affected trial reports, with assessment of impact of trial reports
Topic
Number of 
affected 
publications
If affected trial reports removed
Findings likely to 
change
Unclear if 
findings would 
change
Findings unlikely 
to change
Fracture reviews and meta- analyses 9 4 4 1
Falls reviews and meta- analyses 2 1 0 1
Other reviews and meta- analyses 12 3 3 6
Effectiveness reviews and guidelines 9 5 1 3
Total 32 13 8 11
effectiveness reviews, were not listed on Web of Science 
or Scopus. Of the 68 citing publications indexed on Ovid 
Medline, 27 were systematic reviews, meta- analyses and 
narrative reviews, 9 effectiveness reviews and guidelines, 
and 32 clinical trial reports.
reviews and meta-analyses
The 12 affected trial reports were included in 23 system-
atic reviews, meta- analyses and narrative reviews, covering 
a broad spectrum of topics, including prevention of falls 
and fractures, treatment of psychiatric symptoms and the 
role of homocysteine in disease.18–43 Four further reviews 
and meta- analyses cited but did not include any data from 
affected trial reports in their analyses.44–47
Fracture reviews and meta-analyses
Nine reviews and meta- analyses relating to hip fracture 
prevention were identified that cited at least one affected 
trial report. The findings of four were likely to change 
copyright.
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following the removal of the affected trial reports (see 
table 2).18 21 22 24
Two systematic review authors did not express caution 
that their findings were derived from one group of inves-
tigators. The systematic review by Zhang et al21 (three 
citations, most recent December 2016) only included 
affected trial reports.21 However, the authors noted the 
lack of generalisability from Japanese- only populations. 
The systematic review by Zhao et al22 focused on hip frac-
ture and bone mineral density outcomes in Alzheimer’s 
disease; affected trial reports were the only sources of 
bone mineral density data.
Cockayne et al18 undertook a meta- analysis of vitamin 
K for fracture prevention (217 citations, August 2018) 
which influenced Japanese osteoporosis guidelines. The 
reduction in hip fractures was statistically and clinically 
significant with an OR of 0.23 and narrow CI (95% CI 
0.12 to 0.47). However, Cockayne et al18 also included a 
sensitivity analysis to investigate the effect of removing 
the three affected trial reports.8–10 This analysis changed 
the result to a statistically non- significant result with wide 
confidence intervals (OR 0.30, 95% CI 0.05 to 1.74). The 
reason given for conducting the sensitivity analysis was 
that the trial populations were from a single centre and 
included participants at much higher risk of fractures 
than other trials. The authors expressed some caution 
when interpreting the main findings of their review 
because of the uncertainty introduced by this sensitivity 
analysis and their conclusions—that vitamin K helps to 
prevent hip fractures—would be different if the affected 
trial reports were omitted. Importantly, this 2006 meta- 
analysis, without any caveat related to the sensitivity anal-
ysis, is the sole evidence cited for vitamin K preventing 
vertebral and non- vertebral fractures in the journal publi-
cation of the 2011 Japanese guidelines for osteoporosis23 
(122 citations, October 2018). In 2018, in response to 
retractions, Cockayne’s group published a letter of expla-
nation and corrected article,19 20 removing the three 
affected trial reports, with the revised OR for hip fracture 
of 0.30 (95% CI 0.05 to 1.74).
One affected trial report14 was judged to have influ-
enced the strength of a review’s conclusions. This was a 
narrative review of B vitamins and bone health24 (eight 
citations, September 2018). The affected trial report14 
showed that B vitamins significantly reduced hip frac-
tures, contrary to the evidence cited that most studies 
did not demonstrate reduced fracture risk. The authors 
noted that the results of one affected trial report14 were 
unusual and speculated that improvements in neurolog-
ical and cognitive function from B vitamins would prevent 
fall- related fractures. We judged that without the affected 
trial report the review’s conclusions of lack of efficacy of 
the intervention would be stronger.
Cases where we were unable to reanalyse meta- analyses 
after removal of affected trial reports would have been 
facilitated by authors providing open access to all their 
data. For four meta- analyses, it was unclear if omission of 
the affected trial reports would alter the findings (Richy 
et al25 79 citations, October 2018; Richy et al26 91 cita-
tions, February 2018; Murad et al27 26 citations, August 
2018; Yang et al28 54 citations, October 2018). Clarifica-
tion of the impact of the affected trial reports requires 
the reviews’ authors to repeat their meta- analyses with 
and without the affected trial reports. The citation of one 
affected trial report11 in the review by McCarus et al29 is 
little more than a passing reference and data from the 
trial report were not used.
Falls reviews and meta-analyses
Two affected reviews and meta- analyses related to the 
prevention of falls were identified, since the affected trial 
reports also provided data on falls.
The results from one affected trial report10 changed 
the findings for a combined treatment (calcium, vitamin 
D and vitamin K for falls prevention). One Cochrane 
review on the prevention of falls in the community30 (756 
citations, November 2018) included an unpooled meta- 
analysis of data from one affected trial report10 and one 
other trial of calcium alone, relating to the number of 
fractures caused by falling. The analysis shows a large, 
statistically significant, reduction in fracture risk in the 
intervention group from the affected trial report (risk 
ratio 0.13, 95% CI 0.04 to 0.43), and a null effect in the 
other trial48 (risk ratio 0.90, 95% CI 0.69 to 1.16).
Data from two affected trial reports were included in 
unpooled meta- analyses in the review by Batchelor et al31 
(65 citations, September 2018), in which the affected trial 
report data were not outlying.
Other reviews and meta-analyses
Twelve other affected reviews and meta- analyses were 
identified. Removing affected trial reports from three 
would likely alter their conclusions. The conclusion of 
one systematic review on interventions for osteoporosis 
(Hermann et al,32 65 citations, 2018) that B- vitamins were 
likely to reduce the risk of osteoporosis was supported 
by data from an affected trial report,14 which showed a 
reduction in hip fractures in the intervention group. The 
review’s authors note several limitations in the affected 
trial report, but commented on its ‘very promising’ 
results.
In their review of vitamin D and Parkinson’s disease, 
Peterson et al33 (16 citations, 2017) base their conclu-
sions almost entirely on data from four affected trial 
reports.8 9 15 16
Three affected trial reports8 15 16 were cited in the review 
by Binks and Dobson34 (one citation, 2017) as evidence 
for the benefit of vitamin D and bisphosphonates in 
people with Parkinson’s disease. Although Binks and 
Dobson were careful to draw attention to the limitations 
of the trial reports, nonetheless their conclusions would 
be substantially different without these data.
Affected trial reports were included in three reviews 
(Alibhai et al35 118 citations, October 2018; Carda et al36 
24 citations, September 2018; Simpson et al37 14 cita-
tions, April 2018) where it was unclear if findings would 
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be altered by the omission of the affected reports’ data. 
The conclusions of six systematic reviews were unlikely to 
change if data from affected trial reports were omitted.38–43
Systematic reviews excluding affected trial reports
A further four systematic reviews cited but did not include 
affected trial reports in their reviews as a result of existing 
concerns with data,44–46 or awaiting responses to enqui-
ries about data.47 One was a Cochrane review by one of 
the authors of this paper, with concerns dating back to 
2006.44 Another Cochrane review, whose authors corre-
sponded with AA, excluded trials for not fitting study 
inclusion criteria.45 Latham et al46 appeared to exclude 
one trial8 because of its poor quality from their review 
of vitamin D for falls prevention and other outcomes. 
Verheyden et al47 categorised two affected trial reports as 
awaiting assessment11 12 in their Cochrane review of falls 
prevention after stroke.
effectiveness reviews and guidelines
Affected trial reports were cited in nine effectiveness 
reviews and clinical guidelines (one published in Scot-
land, the others in the USA), for stroke,49 fracture preven-
tion50–55 and fall and injury prevention.56 Removing these 
affected trial reports would likely alter findings in five 
reviews and guidelines.51–54 56
The effectiveness review from the US AHRQ in 2007 
on fracture prevention51 (no citation count avail-
able) included six affected trial reports in their Table 
56,6 8 11–13 15 which are the only trials cited for bisphos-
phonates preventing fractures in high risk falls patients. 
In addition, three affected trial reports11–13 are the only 
evidence used to support the 2.5 mg dose of risedronate 
for preventing hip fracture. This dose of risedronate 
does not have marketing approval in the USA (https://
www. fda. gov/ downloads/ drugs/ deve lopm enta ppro valp 
rocess/ ucm071436. pdf), but does in Japan (https://www. 
ajinomoto. com/ en/ presscenter/ press/ detail/ g2009_ 
07_ 31. html).
The publication in the Annals of Internal Medicine52 from 
this AHRQ review has been cited 346 times, including 
September 2018, and it references four of the six above- 
mentioned affected trial reports, with these reports being 
the sole sources of data evidencing the reduction in 
fractures from bisphosphonates in patients with Parkin-
son’s disease, Alzheimer’s disease or stroke. The linked 
guideline from the American College of Physicians53 (114 
citations, March 2018) references the same four affected 
trial reports as evidence for bisphosphonate use in popu-
lations at increased risk of falls.
When the AHRQ review was updated in 201254 (no 
citation count available), it included evidence from five 
affected trial reports,11–13 15 16 with no new trials from 
other authors providing data for risedronate 2.5 mg/day 
in the prevention of hip fracture. The effectiveness review 
also states that this dose is equivalent to higher doses of 
risedronate.
A 2008 evidence- based handbook for nurses56 (no cita-
tion count available) contains the statement that risedro-
nate is effective in preventing fractures in older women, 
older men who have had a stroke and older women with 
Alzheimer’s disease, based entirely on two affected trial 
reports.12 13
It was unclear whether exclusion of the affected trial 
reports would alter findings in one report. American 
stroke guidelines49 (1230 citations, November 2018) 
used evidence from one report14 of vitamin B12 and folate 
supplementation as the only evidence when discussing 
fracture prevention among patients with a recent isch-
aemic stroke. However, ‘routine’ supplementation of 
vitamins was not recommended, so we judged that it was 
unclear if findings, related to higher risk patients, would 
change without this one report.
Findings of three reviews were unlikely to change 
following exclusion of affected trial reports. The updated 
2017 American College of Physicians’ guidelines55 (74 
citations, October 2018) includes two of the affected trial 
reports on 2.5 mg daily risedronate13 16 in its overview of 
the evidence for the use of risedronate from the AHRQ 
review,54 but does not discuss the specific issue of the lower 
dose of risedronate. Guidelines from Scotland relating to 
osteoporosis and fractures50 express caution about using 
the affected trial report on vitamin B12 and folate supple-
mentation14 in recommendations: ‘As this was a Japanese 
population that had suffered a stroke, it is not certain 
how relevant the findings are to a Scottish population.’ A 
guideline from AHRQ57 excluded one trial report8 from 
its review of interventions to prevent falls in older people. 
The reason for exclusion was that the report did not focus 
on the outcome of interest, that is, the rate of falls or 
number of fallers, despite what appeared to be relevant 
falls data in the affected trial report.
trials
We identified 32 clinical trial reports (including 27 RCTs) 
which cited affected trial reports. In eight cases,58–65 
affected trial reports contributed to the rationale for 
undertaking further RCTs. These RCTs are listed in 
table 3. Seven trials discussed one or more of the affected 
trial reports in their introduction sections, and five trials 
in their discussion sections. The strongest suggestion 
of influence in study design or rationale comes from 
the RCT by van Wijngaarden et al,65 published in 2014, 
which discusses two RCTs in people at risk of cardiovas-
cular disease or with cerebrovascular disease which had 
been unable to demonstrate B vitamins preventing frac-
tures. These RCTs were contrasted with the affected trial 
report,14 which reported a reduction in hip fractures in 
stroke survivors. van Wijngaarden et al then state that 
‘Given the conflicting results and low generalizability 
to the general older population, further investigation is 
needed.’ van Wijngaarden et al’s trial randomised 2919 
participants to B vitamins or placebo for 2 years, and 
found no treatment effect on osteoporotic fractures.65
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Table 3 RCT reports in which affected publications by Sato and colleagues are included in the justification for the trial
RCT
Affected trial 
report cited Intervention, patient group and outcome Sample size Follow- up
Bauman 200558 6 1 alpha- hydroxyvitamin D2 for reducing bone loss in spinal 
cord injury patients
40 24 months
Berendsen 201359 14 Vitamins D, B12 and folate for slowing functional decline in 
people over 65 years
1250 12 months
Binkley 200960 7 10 Vitamin K for bone density and biochemical markers in 
postmenopausal women
381 12 months
Emaus 201361 7 9 10 Vitamin K for bone density and biochemical markers in 
postmenopausal women
334 12 months
Grieger 200962 14 Multivitamins for improving bone quality, falls and 
nutritional status in care home residents
92 6 months
Hermann 200763 14 B- vitamins for bone density and biochemical markers in 
people with osteoporosis
47 12 months
Rucklidge 201264 14 Multivitamins and minerals for stress in adults 91 2 months
Van Wijngaarden 
201465
14 Vitamins B12 and folate for preventing fractures in people 
≥65 years with elevated homocysteine status
2919 24 months
RCT, randomised controlled trial.
In another eight RCTs (not shown in table 3), the 
authors cited affected trial reports to draw attention to 
the disparities between their own findings and those 
reported.66–73 It appeared unlikely that the affected trial 
reports contributed to the rationale for these trials.
DiSCuSSiOn
Our analysis suggests that affected trial reports are likely 
to have had an adverse impact on clinical care and other 
research. By 2016, affected trial reports were widely 
cited in the published literature of particular relevance 
to older people with Parkinson’s disease, stroke or 
Alzheimer’s disease, where, despite their generally small 
sample size and number of events, they dominated the 
literature for fracture prevention. Despite recommenda-
tions for caution in deriving conclusions from data from 
a very limited number of authors and centres,74 75 authors 
of reviews that included affected trials rarely expressed 
caution.21 22 We were unable to identify published or 
registered ( ClinicalTrials. gov) RCTs of bisphospho-
nates in these patient groups by other research groups. 
Thus, other researchers (and funders) may have been 
dissuaded from undertaking further trials by evidence 
from these affected trial reports. It was apparent that 
some systematic reviews and guidelines, particularly for 
the earlier three patient groups, would be different for 
vitamin K and risedronate 2.5 mg/day if the affected trial 
reports were removed, and that some affected system-
atic reviews and guidelines have themselves been widely 
disseminated.18 23 30 49 52 However, we do not know which 
parts of these systematic reviews and guidelines have 
been influential. With one exception,18–20 authors and/
or journals of citing publications have either not iden-
tified that their publications have been compromised, 
or decided no action is required, although the latter 
seems unlikely. To our knowledge, bibliographic data-
base/journal/publisher/guideline developer structures 
are not established that permit systematic identification 
and correction of publications that are affected by the 
inclusion of research with compromised integrity. Even 
if removing the affected trial reports did not influence 
their conclusions, citing authors should publish an 
update. This should give details of their examination 
of the impact of the correction or retraction on their 
own work, and confirm that changes are not required 
or have been made. This would remove uncertainty in 
the interpretation of their work.76 77 This could be aided 
by publishing an amended article, with an updated 
version number, as has been suggested by Barbour and 
colleagues.78
Our assessment in August 2016 relates to publica-
tions up to that time. New, affected publications have 
continued to accumulate. We only assessed the impact of 
the 12 likely most influential affected trial reports (based 
on hip fracture outcomes and publication in journals 
with impact factor >4) from the 33 we originally inves-
tigated.1 The remaining 21 affected trial reports may 
also have been influential. For example, the 2007 AHRQ 
report by MacLean and colleagues51 on treatments to 
prevent fractures includes six affected trial reports that 
we did not assess. It was not always possible to fully assess 
the impact of affected trial reports, because published 
data in affected publications were insufficient to allow us 
to replicate analyses after excluding affected trial reports. 
Examining impact in a network meta- analysis such as 
that by Murad and colleagues27 would be difficult, even 
if data were available. Narrative reviews can be particu-
larly vulnerable to studies with research misconduct,75 
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box 1 Some possible solutions for minimising the impact 
of retracted research reports
 ► Journals and publishers should ensure that expressions of concern, 
retractions or corrections are appropriately flagged so that they are 
immediately available to be listed as such on bibliographic databas-
es, including that of Retraction Watch, and search engines.
 ► Publishers should sign up to The CrossMark (https://www.crossref.
org/services/crossmark/), an initiative to take readers to the current 
version of the paper, which should include expressions of concern, 
retractions or corrections.
 ► After institutional investigations have found that misconduct has 
taken place, institutions could notify corresponding, first authors 
and senior authors of citing publications.
 ► Listing an expression of concern, retraction or correction on bib-
liographic databases should generate automatic alerts to corre-
sponding, first authors and senior authors of citing publications.
 ► Retraction Watch’s database of retractions, linked to reference man-
agement software, should be used to regularly scan researcher’s 
personal reference libraries.94
 ► Journals and their publishers could help to prevent inappropriate 
citations by themselves checking or requiring authors to check their 
reference list for expressions of concern, retractions or corrections.
 ► Organisations responsible for publications, which are not usual-
ly listed on bibliographic databases, e.g. clinical guideline groups, 
should regularly check Retraction Watch’s database against their 
reference lists, or ensure their guidelines are listed on bibliographic 
databases.
 ► Authors of citing publications should publish an amendment, or a 
reassurance that the publication is unaffected, with a link to the 
affected publication.
and assessing impact in narrative reviews was often more 
challenging, as others have found.74
We only investigated affected trial reports’ impact on 
published research. They could also have influenced 
grant applications, educational events, media coverage 
and social media, evaluation of which require a very broad 
range of information sources. Most importantly, we could 
not directly establish the effect on patients from clinical 
practices informed by the unreliable research. We did 
not examine the impact of reviews and systematic reviews 
authored by the group of researchers who published 
the affected trial reports, which includes more than 30 
reviews and meta- analyses. Such active dissemination by 
self- citation in cases of prolific misconduct also occurred 
in the Reuben and Fujii cases.74 79
We have probably missed guidelines in our evaluation 
of citing publications, since these are poorly covered by 
indexing databases. AHRQ full guidelines51 54 were iden-
tified through linked journal articles, and Scottish Inter-
collegiate Guidelines Network (SIGN) guidelines from 
personal databases.50 Thus, we have probably underesti-
mated the impact of these 12 trial reports.
Our findings are consistent with those of others who 
have investigated the impact of publications affected by 
research misconduct on subsequent publications and 
systematic reviews.74 76 80–83 In the Scott Reuben case, 
almost half of Reuben’s articles on perioperative anal-
gaesia were still being cited more than 5 years after their 
retraction,81 and his reports widely infiltrated literature 
in this area.84
Retractions of affected trial reports examined here 
started only in 2016, but concerns about research by this 
Japanese research group had been expressed as early 
as 2004–2007 by other groups, so that delays in investi-
gation also increased the impact of this misconduct.85–89 
Mott and colleagues found a 46% reduction in citations 
of randomised clinical trial reports in the first year after 
retraction,83 and retractions also reduce subsequent 
publication by authors associated with misconduct.90
It seems systems have not changed to mitigate the 
impact of misconduct, once it is identified, more than 
10 years since these issues were highlighted by Sox 
and Rennie.76 van der Vet and Nijveen91 argued on the 
basis of a single, preclinical case study that indirect cita-
tions did not contribute to the propagation of research 
misconduct. However, for randomised trials in clinical 
areas affecting systematic reviews and guidelines further 
propagation is likely, as we show in the case of the system-
atic review by Cockayne et al18 and its influence on Japa-
nese osteoporosis guidelines.23 In the case of Fujii’s 
extensive publications, the effect of his misconduct on 
the management of postoperative nausea and vomiting 
appears to have only been minimised by the large volume 
of publications from other authors.79 In a recent paper, 
analyses by Fanelli and Moher92 suggested that meta- 
analyses may overestimate their summary effect sizes 
when they include studies later retracted for issues with 
data, methods or results.
Delays in the processes of investigating, correcting or 
retracting research misconduct add to the impact on 
patients, funders and other researchers. Delays in retrac-
tion by journals, even in response to official notification 
by investigating authorities, continue to be problematic 
and contribute to the impact of retracted work.93 Once 
a retraction is posted by a journal all bibliographic data-
bases and search engines should be swiftly updated. 
This was not the case with affected trial reports, which 
were retracted but not always listed as retracted on Ovid 
Medline and PubMed, in some cases more than 2 years 
later. Journals and their publishers could help to prevent 
the citation of retracted studies by themselves checking 
or requiring authors to check their reference list against 
Retraction Watch’s database (http:// retractiondatabase. 
org/ RetractionSearch. aspx?) before submission.77 Zotero 
software that is linked to Retraction Watch’s database,94 or 
ReTracker linked to Retractions in PubMed,95 might facil-
itate authors’ awareness of retractions. Clearly marked, 
retracted articles and properly informative retraction 
notices should be linked on journals’ websites and both 
should be freely accessible.76 80
Research misconduct can have widespread detrimental 
effects on subsequent research initiatives and clinical 
practice. Some possible solutions to minimise the impact 
of retracted publications are given in box 1, but there 
remains no overarching body with the commitment 
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to coordinate managing the consequences of proven 
research misconduct.
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